ICLUSIG®
(ponatinib) tablets

Iclusig® REMS

FDA REQUIRED REMS SAFETY INFORMATION

Iclusig® (ponatinib)
- **Revised indications**
- **New safety information about risk of vascular occlusion**
- **New dosing considerations**

<Date>

<Name, MD>
<Address>
<City, State, Zip>

<Dear Dr. NAME:>

IMPORTANT SAFETY UPDATE

The FDA has required ARIAD Pharmaceuticals, Inc., to distribute this update to the [Professional Organization] as part of their Iclusig REMS (Risk Evaluation and Mitigation Strategy) program. We request that you inform your members about the following **labeling updates** and **serious risks of Iclusig:**

- **Revised indications have been limited to:**
  - Treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
  - Treatment of adult patients with chronic phase, accelerated phase, or blast phase CML or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated

- **New safety information about risk of vascular occlusion in Boxed Warning**
  - Arterial and venous thrombosis and occlusions have occurred in at least **27%** of Iclusig clinical trial patients

- **New dosing considerations**
  - **Optimal dosing has not been identified.** In clinical trials, the starting dose of Iclusig was 45 mg administered orally once daily. However, 59% of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy

ICLUSIG®
(ponatinib) tablets

Iclusig® REMS

A nonpromotional fact sheet, reviewed by the FDA, with more detailed safety information is available here: www.iclusigREMS.com

This letter does not contain the complete safety profile for Iclusig® (ponatinib). Please visit www.iclusigREMS.com for more information.

Sincerely,

Frank G. Haluska, MD, PhD
Chief Medical Officer
Senior Vice President, Clinical Research and Development
ARIAD Pharmaceuticals, Inc.

ARIAD

Iclusig is a registered trademark of ARIAD Pharmaceuticals, Inc. © 2013 ARIAD Pharmaceuticals, Inc. All rights reserved.